The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema.
Hereditary angioedema (HAE) manifests as intermittent, painful attacks of submucosal oedema affecting the larynx, gastrointestinal tract or limbs. Currently, acute treatment is available in Europe but not USA, and requires intravenous administration of a pooled blood product. HAE is most likely caused by dysinhibition of the contact cascade, resulting in overproduction of bradykinin. DX-88 (ecallantide, Dyax Corp.) is a highly specific recombinant plasma kallikrein inhibitor that halts the production of bradykinin and can be dosed subcutaneously. In a placebo-controlled Phase II trial in patients with HAE, DX-88 resulted in significant improvement in symptoms compared with placebo. A Phase III trial is ongoing. This review explains the pathophysiology of HAE and the mechanism by which DX-88, a non-intravenous, nonplasma-derived therapy, might improve the disease, and discusses the clinical course of HAE and available treatments. Finally, it explores the potential value and efficacy of DX-88 in treating HAE.
Levy
Jerrold H
JH
Emory University Hospital, 1364 Clifton Road, North East Atlanta, GA 30322, USA. jerrold.levy@emoryhealthcare.org
O'Donnell
Penrose S
PS
D000799:Angioedema / Q000188:drug therapy* / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D000818:Animals; D004198:Disease Susceptibility; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007610:Kallikreins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D007705:Kinins / Q000378:metabolism; D010455:Peptides / Q000627:therapeutic use
D004791:Enzyme Inhibitors; D007705:Kinins; D010455:Peptides; C511194:ecallantide; D007610:Kallikreins